314 related articles for article (PubMed ID: 21769307)
1. Small molecule inhibitors of human papillomavirus protein - protein interactions.
D'Abramo CM; Archambault J
Open Virol J; 2011; 5():80-95. PubMed ID: 21769307
[TBL] [Abstract][Full Text] [Related]
2. Genital human papillomavirus infections: current and prospective therapies.
Stanley MA
J Gen Virol; 2012 Apr; 93(Pt 4):681-691. PubMed ID: 22323530
[TBL] [Abstract][Full Text] [Related]
3. Small Molecule Inhibitors of Human Papillomavirus: A Review of Research from 1997 to 2021.
Duncan CL; Gunosewoyo H; Mocerino M; Payne AD
Curr Med Chem; 2023 Jul; ():. PubMed ID: 37448363
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
Rosales R; López-Contreras M; Cortes RR
J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets for human papillomaviruses: prospects for antiviral therapy.
Phelps WC; Barnes JA; Lobe DC
Antivir Chem Chemother; 1998 Sep; 9(5):359-77. PubMed ID: 9875390
[TBL] [Abstract][Full Text] [Related]
6. Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses.
Alvarez-Salas LM; Benítez-Hess ML; DiPaolo JA
Antivir Ther; 2003 Aug; 8(4):265-78. PubMed ID: 14518695
[TBL] [Abstract][Full Text] [Related]
7. Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways.
Jones EE; Wells SI
Curr Mol Med; 2006 Nov; 6(7):795-808. PubMed ID: 17100604
[TBL] [Abstract][Full Text] [Related]
8. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity.
Hebner CM; Laimins LA
Rev Med Virol; 2006; 16(2):83-97. PubMed ID: 16287204
[TBL] [Abstract][Full Text] [Related]
9. [Genomic organization and proteins of human papillomavirus].
Alp Avcı G
Mikrobiyol Bul; 2012 Jul; 46(3):507-15. PubMed ID: 22951665
[TBL] [Abstract][Full Text] [Related]
10. [Virological and carcinogenic aspects of HPV].
Prétet JL; Charlot JF; Mougin C
Bull Acad Natl Med; 2007 Mar; 191(3):611-23; discussion 623. PubMed ID: 18072657
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus proteins as prospective therapeutic targets.
Pang CL; Thierry F
Microb Pathog; 2013 May; 58():55-65. PubMed ID: 23164805
[TBL] [Abstract][Full Text] [Related]
12. Targeting human papillomavirus genome replication for antiviral drug discovery.
Archambault J; Melendy T
Antivir Ther; 2013; 18(3):271-83. PubMed ID: 23615820
[TBL] [Abstract][Full Text] [Related]
13. The SMC5/6 Complex Interacts with the Papillomavirus E2 Protein and Influences Maintenance of Viral Episomal DNA.
Bentley P; Tan MJA; McBride AA; White EA; Howley PM
J Virol; 2018 Aug; 92(15):. PubMed ID: 29848583
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus: E6 and E7 oncogenes.
Boulet G; Horvath C; Vanden Broeck D; Sahebali S; Bogers J
Int J Biochem Cell Biol; 2007; 39(11):2006-11. PubMed ID: 17768080
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Cellular MEK/ERK Signaling Suppresses Murine Papillomavirus Type 1 Replicative Activities and Promotes Tumor Regression.
Luna AJ; Young JM; Sterk RT; Bondu V; Schultz FA; Kusewitt DF; Kang H; Ozbun MA
bioRxiv; 2023 Apr; ():. PubMed ID: 36993217
[TBL] [Abstract][Full Text] [Related]
17. The Deacetylase SIRT1 Regulates the Replication Properties of Human Papillomavirus 16 E1 and E2.
Das D; Smith N; Wang X; Morgan IM
J Virol; 2017 May; 91(10):. PubMed ID: 28275188
[TBL] [Abstract][Full Text] [Related]
18. Papillomavirus E6 and E7 proteins and their cellular targets.
Wise-Draper TM; Wells SI
Front Biosci; 2008 Jan; 13():1003-17. PubMed ID: 17981607
[TBL] [Abstract][Full Text] [Related]
19. HPV-16 E2 physical status and molecular evolution in vivo in cervical carcinomas.
Kahla S; Kochbati L; Chanoufi MB; Maalej M; Oueslati R
Int J Biol Markers; 2014 Mar; 29(1):e78-85. PubMed ID: 24170557
[TBL] [Abstract][Full Text] [Related]
20. Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility.
Morrison MA; Morreale RJ; Akunuru S; Kofron M; Zheng Y; Wells SI
J Virol; 2011 Oct; 85(20):10487-98. PubMed ID: 21835799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
